Drug treatment for multidrug-resistant Acinetobacter baumannii infections

Matteo Bassetti, Elda Righi, Silvano Esposito, Nicola Petrosillo, Laura Nicolini

Research output: Contribution to journalArticlepeer-review


Acinetobacter baumannii has emerged in the lost decades as a major cause of healthcare-associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is a rapidly emerging pathogen in healthcare settings, where it causes infections that include bacteremia, pneumonia, meningitis, and urinary tract and wound infections. Antimicrobial resistance poses great limits for therapeutic options in infected patients, especially if the isolates are resistant to the carbapenems, Other therapeutic options include sulbactam, aminoglycosides, polymixyns and tigecycline. The discovery of new therapies coupled with the development of controlled clinical trial antibiotic testing combinations and the prevention of transmission of MDR Acinetobacter infection are essential to face this important, hospital problem.

Original languageEnglish
Pages (from-to)649-660
Number of pages12
JournalFuture Microbiology
Issue number6
Publication statusPublished - 2008


  • Acinetobacter baumannii
  • Antibiotic
  • Colistin
  • Imipenem
  • Meropenem
  • Resistance
  • Rifompin
  • Sulbactam
  • Therapy
  • Tigecycline

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)


Dive into the research topics of 'Drug treatment for multidrug-resistant Acinetobacter baumannii infections'. Together they form a unique fingerprint.

Cite this